In parenteral manufacturing for non-food equine and companion species, aminophenazone is typically dissolved at 50 mg/mL, equivalent to 5.0% w/v, in water for injection, followed by pH adjustment to 5.5–6.5 with 0.1 M hydrochloric acid or sodium hydroxide. The compliance anchor for this format is EU GMP Annex 1 for sterile medicinal products, read with Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 for bacterial endotoxins, and Ph. Eur. 2.9.19 for particulate contamination; extemporaneous veterinary hospital preparation in the United States falls under USP <797> only when patient-specific and conducted outside industrial GMP. The formulation addition ratio is fixed at 5.0% w/v API, with 0.9% w/v sodium chloride as tonicity adjuster, 0.05% w/v sodium metabisulfite as antioxidant, and water for injection q.s. to final volume. Downstream dissolution is carried out in a jacketed 316L stainless steel vessel with bottom-mounted magnetic stirrer and nitrogen overlay at 20–25 °C; the batch is passed through a 0.45 µm polypropylene prefilter and a 0.22 µm sterilising-grade polyethersulfone filter before aseptic filling into Type I glass vials in an ISO 14644-1 Class 5 environment. Terminal moist-heat sterilisation at 121 °C for 15 minutes is not universally recommended for aminophenazone solutions because published data on colouration and pyrazolone ring degradation under saturated steam is limited; terminal filtration plus aseptic fill therefore remains the common industrial route. Finished formats are 10 mL single-dose vials and 20 mL multi-dose vials sealed with bromobutyl rubber stoppers and aluminium crimp caps. Vials are stored in amber cartons at 20–25 °C with protection from light. Aminophenazone must not be used in animals intended for human consumption; this is a binding restriction because no maximum residue limit is established in EU Regulation (EU) No 37/2010, and batch release documentation must include a non-food species declaration.

How Does Direct-Fill Capsule Production Handle Aminophenazone’s Solubility and Content Uniformity?

Direct-fill capsule production for companion animal pharmacies requires attention to both the high aqueous solubility of aminophenazone and its low melting point of 107–109 °C, which can soften during high-shear milling if the mill head exceeds 40 °C. The compliance framework includes USP <795> for non-sterile compounding, USP <905> for uniformity of dosage units, Ph. Eur. 2.9.5 for uniformity of mass, and ICH Q3D for elemental impurities. A representative working formula for a size 3 hard gelatin capsule delivering 50 mg aminophenazone uses a total fill weight of 160 mg; the API addition ratio is therefore 31.25% w/w, combined with 63.25% w/w lactose monohydrate 80M, 4.0% w/w crospovidone, 1.0% w/w colloidal silicon dioxide, and 0.5% w/w magnesium stearate. The downstream process consists of delumping the API through a 500 µm stainless steel sieve, geometric dilution with the lactose fraction in a 100 L twin-shell blender at 15 rpm for 20 minutes, addition of crospovidone and colloidal silicon dioxide, and final lubrication with magnesium stearate for 3 minutes. Capsule filling is performed on a semi-automatic or fully automatic tamping-pin machine at 25,000 capsules per hour with a reject threshold of ±5.0% individual weight deviation and automatic disintegration sampling every 30 minutes. The finished capsule formats are 30-count and 100-count HDPE bottles with induction-sealed closures and child-resistant caps, labelled strictly for non-food companion animals because aminophenazone is not authorised for food-producing species in the EU or other major markets.

Tablet manufacturing for veterinary wholesalers serving non-food companion animal markets incorporates aminophenazone at 40.0% w/w in a 250 mg core to deliver 100 mg API per tablet, because the low melting point of 107–109 °C precludes high-shear dry milling but remains manageable during wet granulation. The compliance anchor for this scenario is EU GMP Part I Chapter 3, together with Ph. Eur. 2.9.5, Ph. Eur. 2.9.7 for friability of uncoated tablets, USP <711> for dissolution, and USP <905> for dose uniformity. The complete core formula is 40.0% w/w aminophenazone, 38.5% w/w microcrystalline cellulose PH102, 10.0% w/w lactose monohydrate 80M, 5.0% w/w crospovidone, 4.0% w/w povidone K30, 1.0% w/w colloidal silicon dioxide, and 1.5% w/w magnesium stearate. Downstream processing starts with a 300 L high-shear mixer operating at impeller speed 120 rpm and chopper speed 1,000 rpm for 5 minutes, followed by addition of an aqueous povidone K30 binder solution at 8.0% w/w solids until granulate endpoint; the wet mass is discharged through a 4.0 mm mesh and dried in a fluid-bed dryer with inlet air at 55–60 °C until loss on drying is below 2.0% w/w. The dried granulate is dry-screened through an 850 µm mesh, blended with crospovidone, colloidal silicon dioxide, and magnesium stearate, and compressed on a 16-station rotary press with B-tooling at turret speed 30–50 rpm, precompression 5–8 kN, and main compression 10–18 kN. Hardness is maintained at 60–90 N, friability below 0.8% w/w, and disintegration below 15 minutes in 0.1 M hydrochloric acid at 37 °C. Finished tablets are film-coated with an HPMC 6 cps system to 3.0% weight gain and packaged in PVC/PVDC aluminium blisters of 10 or 100 tablets. Because film coating raises the core temperature to 40–45 °C, the process must be validated to avoid granulate softening and embossing wear.

When Premix Granulation Targets Zoo and Sanctuary Non-Food Species

Because aminophenazone-contaminated feed for food-producing animals would create immediate residue non-compliance, premix and granule formats are confined to zoo, sanctuary, and permanently non-food species only. The regulatory anchor is the absence of a maximum residue limit for aminophenazone in EU Regulation (EU) No 37/2010; the applicable manufacturing frame is ICH Q7 for API handling, with Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13 for microbial limits on non-sterile oral powders. The premix addition ratio is typically 2.0–5.0% w/w API in the concentrated premix, with final in-feed dilution normally 0.1–0.5% w/w for zoo ungulates, camelids, and sanctuary equidae permanently excluded from the food chain. Excipients used are 88.0–93.0% w/w dehydrated rice hulls or ground maize starch as carrier, 3.0% w/w povidone K30 as binder, 2.0% w/w sodium aluminium silicate as anti-caking agent, and 0.5% w/w sodium metabisulfite. Production is carried out in a 500 L horizontal ribbon mixer with a spray bar; the binder solution is prepared as 10.0% w/w povidone K30 in purified water and sprayed at 1.5–2.0 L/min while the mixer runs at 40 rpm. The wet granulate is dried in a vacuum fluid-bed dryer at 50 °C until moisture content is below 4.0% w/w, then sieved through 20-mesh and 80-mesh screens to remove fines and agglomerates. Terminal packaging is 5 kg and 25 kg multiwall kraft bags with polyethylene liners, and each bag is sealed with a desiccant pouch because moisture ingress above 60% RH causes caking and potency stratification. Cross-contamination control requires a washout procedure with 5.0 kg of lactose-magnesium stearate flush blend after each campaign and verification of aminophenazone carryover below 10 ppm by HPLC. Published formulation data for aminophenazone premixes in non-food zoo species is limited; the ratios above are working ranges used by contract manufacturers rather than regulatory pharmacopoeial specifications.

Aqueous oral solutions containing aminophenazone present the narrowest stability control window among the common downstream formats, specifically because the pyrazolone ring undergoes accelerated oxidative discolouration when trace copper or iron ions are present. The compliance framework is USP <795> for non-sterile compounding, Ph. Eur. 5.1.3 for oral liquid formulations, ICH Q1A(R2) for stability, and USP <232> for elemental impurities. A representative formula uses 20 mg/mL aminophenazone, equivalent to 2.0% w/v, with 25.0% w/w sorbitol 70% non-crystallising, 0.05% w/v sodium metabisulfite, 0.01% w/v disodium edetate, 0.2% w/v sodium citrate dihydrate, and purified water q.s. to final volume. Downstream processing begins in a 150 L jacketed 316L stainless steel vessel at 25 °C with nitrogen purge; the API is dissolved under high-torque agitation at 200 rpm for 30 minutes, antioxidants and chelating agent are added sequentially, pH is adjusted to 5.5–6.5 with 0.1 M hydrochloric acid, and the solution is filtered through a 0.45 µm polypropylene prefilter and 0.22 µm polyethersulfone final filter. Filling is performed on a 12-head volumetric filler into 60 mL and 120 mL amber polyethylene terephthalate bottles with child-resistant polypropylene caps and induction-sealed polyethylene-foam liners. The units are labelled for non-food companion species only and stored below 25 °C, protected from light; because published data on aminophenazone-specific oral solution stability under long-term conditions is limited, the manufacturer must generate ICH Q1A(R2) data before fixing a shelf-life exceeding 18 months.

Bulk Oral Powders for Prescriber-Directed Administration in Non-Food Species

Bulk oral powder intermediates are produced when the prescribing veterinarian needs dose flexibility that fixed tablets or capsules cannot provide, particularly in very small exotic or juvenile non-food patients. The applicable standards are USP <795> for extemporaneous non-sterile compounding, Ph. Eur. 2.6.12 and Ph. Eur. 2.6.13 for microbiological quality of non-sterile oral powders, and ICH Q7 for API quality. In a 5 g unit-dose sachet delivering 250 mg aminophenazone, the addition ratio is 5.0% w/w API, with 83.0% w/w lactose monohydrate 80M, 10.0% w/w microcrystalline cellulose PH101, 1.0% w/w colloidal silicon dioxide, and 1.0% w/w magnesium stearate. The process uses a 200 L V-blender at 15 rpm for 20 minutes after the API has been delumped through a 355 µm sieve; the blend is discharged into a rotary sachet filler with auger dosing, and fill weight variation is controlled at ±3.0% for each 5 g sachet. Terminal units are heat-sealed aluminium-foil laminate sachets packed 20 per carton, which protect the API from light and ambient moisture. Because the API is freely water-soluble, the sachet content can be dissolved in 50–100 mL of potable water immediately before administration; any unused reconstituted suspension is discarded after 24 hours. This format must not be diverted to food-producing species, and batch records include the statement “not for food-producing animals” as a release criterion.